골수부전 시장 : 인사이트, 역학, 시장 예측(-2034년)

Key Highlights:

• Bone marrow failure could focus on its dual nature as both a rare and complex group of disorders where the body's blood-forming capacity is critically impaired, bridging inherited genetic defects and acquired immune attacks. Unlike many diseases, bone marrow failure syndromes challenge clinicians with their overlapping symptoms, diverse causes, and the urgent need for personalized therapies highlighting the marrow's essential role as the cradle of life's vital cells and the delicate balance required to maintain hematopoietic health.
• Bone marrow failure encompasses a diverse spectrum of disorders broadly classified into inherited and acquired types, Inherited forms, such as Fanconi anemia and dyskeratosis congenita, reveal the profound impact of genetic mutations affecting DNA repair and telomere maintenance, acquired bone marrow failure, including aplastic anemia, typically arises from immune-mediated destruction or environmental exposures later in life.
• Bone marrow failure syndromes (BMFS), including aplastic anemia, are rare, with an annual incidence of 2 to 5 cases per million worldwide. While rare overall, the incidence varies geographically, with higher rates observed in Asia.
• Around 80-85% of Aplastic anemia is known to be acquired, leaving around 15%-20% as an inherited form.
• The most common inherited bone marrow failure is Fanconi anemia which occurs in 1 to 5 cases per million with a carrier frequency of 1 in 200 to 300; however, it is more common in Spanish gypsies (1 in 64).
• Treatment primarily focuses on immunosuppressive therapies, hematopoietic stem cell transplantation, supportive care like transfusions, and newer agents like thrombopoietin receptor agonists (eltrombopag).
• The current FDA-approved drugs for bone marrow failure, includes REVOLADE/PROMACTA (eltrombopag), by Novartis and PIASKY (crovalimab) by Chugai Pharmaceutical/Roche.
• The emerging therapies for bone marrow failure include EXG34217 by Elixirgen Therapeutics and CK0801 by Cellenkos.

DelveInsight's "Bone Marrow Failure (BMF) - Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of bone marrow failure, historical and forecasted epidemiology as well as the bone marrow failure market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The bone marrow failure market report provides current treatment practices, emerging drugs, bone marrow failure share of individual therapies, and current and forecasted systemic bone marrow failure market size from 2020 to 2034, segmented by seven major markets. The report also covers current bone marrow failure treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Bone Marrow Failure Disease Understanding and Treatment Algorithm

Bone Marrow Failure Overview

Bone marrow failure is a serious medical condition in which the bone marrow the soft, spongy tissue inside bones responsible for producing blood cells which fails to produce adequate amounts of one or more types of blood cells, including red blood cells, white blood cells, and platelets. This can lead to symptoms such as fatigue, frequent infections, and excessive bleeding. Bone marrow failure may result from inherited conditions (e.g., Fanconi anemia, dyskeratosis congenita), acquired causes (e.g., aplastic anemia, myelodysplastic syndromes), exposure to toxins or radiation, autoimmune diseases, or certain infections.

Bone marrow failure can be classified into two main types: acquired and inherited. Acquired bone marrow failure typically develops gradually and is not present at birth. While the exact causes are not fully understood, it is often associated with exposure to certain chemicals, medications, or underlying diseases. In contrast, inherited bone marrow failure is caused by genetic mutations passed down from one or both biological parents. This form is often referred to as a bone marrow failure syndrome and usually presents earlier in life. The risk of bone marrow failure increases if one have lymphoma, multiple myeloma, and Myelodysplastic syndrome.

Bone Marrow Failure Diagnosis

The diagnosis of bone marrow failure involves a combination of clinical evaluation, blood tests, and bone marrow examination. Initial blood tests, including a complete blood count (CBC), often reveal low levels of one or more types of blood cells red cells, white cells, or platelets. Additional laboratory tests may assess vitamin levels, viral infections, and markers of immune activity. A bone marrow biopsy is essential to evaluate the structure, cellularity, and presence of abnormal cells within the marrow. In suspected inherited cases, genetic testing may be performed to identify underlying mutations. Together, these diagnostic tools help determine the type, severity, and potential cause of bone marrow failure, guiding appropriate treatment.

In order to determine the underlying causes or complications of bone marrow failure, imaging tests are helpful. Although imaging tests like X-rays, CT scans, or MRIs cannot be used to directly diagnose the failure, they can identify skeletal abnormalities, organ enlargement (such as the liver or spleen), or indications of infection or cancer that may be causing or contributing to bone marrow dysfunction. Differentiating between distinct bone marrow illnesses may be made easier by MRI's ability to evaluate bone marrow composition and identify cellularity alterations. Imaging can also show physical abnormalities that are indicative of hereditary disorders and help confirm the diagnosis.

Bone Marrow Failure Treatment

The underlying cause, severity, and whether bone marrow failure is inherited or acquired all influence how it is treated. In order to control symptoms and avoid complications, supportive care methods including blood transfusions and antibiotics are frequently used. In situations when the immune system is attacking the bone marrow, such as in acquired aplastic anemia, immunosuppressive therapy, which includes medications like cyclosporine and ATGAM (antithymocyte globulin, ATG), may be utilised. Haematopoietic stem cell transplantation, often known as bone marrow transplantation, is a viable remedy for more severe or hereditary cases by substituting healthy donor cells for the damaged marrow. Additional therapies might address certain genetic flaws in inherited diseases, eliminate exposure to dangerous substances, or target underlying illnesses.

Bone Marrow Failure Epidemiology

The bone marrow failure epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the total incident cases of bone marrow failure, total inherited subtypes-specific incident cases of bone marrow failure, age-specific incident cases of bone marrow failure, and etiology-specific incident cases of bone marrow failure in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• Bone Marrow Failure incidence rate is 2 per million in Europe, with higher rates in Asia, perhaps resulting from environmental factors.
• As per the secondary research, a total of 127 patients diagnosed from 1966 through 2007 were registered: 52% had Fanconi Anemia (FA), 17% had Shwachman-Diamond syndrome (SCN), 14% had Diamond-Blackfan Anemia (DBA), 6% had Congenital Amegakaryotic Thrombocytopenia (CAT), 5% had Dyskeratosis Congenita (DC), , and 2% had Thrombocytopenia Absent Radius (TAR).
• Bone marrow failure has triphasic peaks: at 2 to 5 years (inherited is most common), between 20 to 25 years, and after 65 years (most likely due to acquired causes). The incidence of inherited bone marrow failure accounts for 10% to 15% of marrow aplasia and 30% of pediatric bone marrow failure disorders, with approximately 65 cases per million live births every year.
• The 5-year survival was 90.7% in patients aged 0-18 years, 90.5% in patients aged 19-39 years, 70.7% in patients aged 40-59 years, and 38.1% in patients aged >=60 years.

Bone Marrow Failure Drug Chapters

The drug chapter segment of the bone marrow failure report encloses a detailed analysis bone marrow failure marketed and emerging pipeline drugs. It also deep dives into bone marrow failure's pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Currently, REVOLADE/PROMACTA (Novartis) and PIASKY (Chugai Pharmaceutical/Roche), is the FDA-approved drugs for treating bone marrow failure. The drug chapter also helps understand the bone marrow failure clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, and the latest news and press releases.

Marketed Drugs

REVOLADE/PROMACTA (eltrombopag): Novartis

REVOLADE, developed by Novartis and marketed under this name outside the US (known as PROMACTA in the US, is an oral thrombopoietin receptor agonist used to treat thrombocytopenia and severe aplastic anemia (SAA), a type of bone marrow failure. It stimulates bone marrow activity, promoting the production of blood cells especially platelets. Eltrombopag is approved for patients with SAA who are unresponsive to immunosuppressive therapy and is also used in combination with ATG and cyclosporine as part of first-line treatment in select cases.

• In November 2018, Novartis announced that the US Food and Drug Administration (FDA) had expanded the approved use of PROMACTA to include its use as a first-line treatment alongside standard immunosuppressive therapy (IST) for adults and children aged two years and older with severe aplastic anemia (SAA).
• REVOLADE received Breakthrough Therapy Designation (BTD) for treating low platelet counts in individuals exposed to radiation.

PIASKY (crovalimab): Chugai Pharmaceutical/Roche

PIASKY is a humanized monoclonal antibody. It functions as a complement C5 inhibitor, targeting the C5 protein in the complement system to prevent its cleavage into C5a and C5b. This inhibition blocks the formation of the membrane attack complex (MAC), thereby reducing intravascular hemolysis and alleviating symptoms associated with paroxysmal nocturnal hemoglobinuria (PNH).

In August 2024, Roche announced that the European Commission has approved PIASKY (crovalimab), a novel recycling monoclonal antibody that targets the complement protein C5. It is approved for adults and adolescents aged 12 years and older (weighing at least 40 kg) with paroxysmal nocturnal hemoglobinuria (PNH), including both treatment-naive patients and those previously treated with C5 inhibitors.

Emerging Therapies

EXG34217: Elixirgen Therapeutics

EXG-34217 is an investigational autologous gene therapy developed by Elixirgen Therapeutics for treating bone marrow failure associated with telomere biology disorders such as dyskeratosis congenita. It works by modifying the patient's own CD34+ hematopoietic stem cells to express ZSCAN4, a protein that promotes telomere elongation independently of telomerase, aiming to restore healthy blood cell production in cases where critically short telomeres lead to marrow failure.

In February 2025, Elixirgen Therapeutics, announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to EXG-34217, its gene therapy candidate for Telomere Biology Disorders (TBDs). The therapy is currently being evaluated in an ongoing Phase I/II clinical trial (NCT04211714) for patients with TBD-related bone marrow failure. Enrollment is open to individuals aged 12 and older, inclusive of all genders and ethnic backgrounds.

In Februrary 2025, Elixirgen Therapeutics, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EXG-34217, its gene therapy candidate for the treatment of Telomere Biology Disorders (TBDs). The therapy is currently being evaluated in a Phase I/II clinical trial (NCT04211714) targeting patients with TBD-related bone marrow failure. The study is actively enrolling participants aged 12 and older, regardless of gender or ethnicity.

CK0801: Cellenkos

CK0801 is a first-in-class allogeneic cord blood-derived regulatory T-cell (Treg) therapy developed by Cellenkos to treat bone marrow failure syndromes, including aplastic anemia. Its mechanism involves homing to the inflamed bone marrow microenvironment and suppressing overactive cytotoxic T cells, thereby calming inflammation and potentially reversing hematopoietic arrest.

In June 2019, Cellenkos, has launched a Phase I clinical trial for CK0801, an allogeneic cord blood-derived regulatory T-cell therapy targeting bone marrow failure syndromes such as aplastic anemia, hypoplastic myelodysplasia, and primary myelofibrosis. CK0801 works by delivering healthy regulatory T-cells that suppress harmful cytotoxic T-cells in the bone marrow, reducing inflammation and restoring normal blood cell production.

Drug Class Insight

Gene transference

Gene transference is a therapeutic technique that involves introducing genetic material into a patient's cells to correct or compensate for a faulty gene. This is typically achieved using viral or non-viral vectors to deliver the gene into target cells, where it can either integrate into the genome or exist temporarily to produce a functional protein. By restoring or enhancing normal cellular function, gene transference offers a promising approach to treating a wide range of genetic and acquired diseases, including certain forms of bone marrow failure.

Bone Marrow Failure Market Outlook

Bone marrow failure (BMF) syndromes, including aplastic anemia and related disorders, involve the bone marrow's inability to produce sufficient blood cells, leading to anemia, increased infections, and bleeding risks. These conditions, often resulting from immune-mediated destruction or genetic mutations, require complex management strategies encompassing immunosuppressive therapies, thrombopoietin receptor agonists like PROMACTA/REVOLADE, and hematopoietic stem cell transplantation (HSCT), which remains the only curative approach for many patients.

Key marketed drugs include thrombopoietin receptor agonists like eltrombopag that stimulate blood cell production, and supportive drugs for related marrow failure conditions. Research into novel therapies, including gene therapy and allogeneic regulatory T cell products such as CK0801, and EXG34217 is also progressing, aiming to improve outcomes by addressing underlying immune dysfunctions and genetic causes.

These pipeline therapies have the potential to significantly transform the treatment landscape of bone marrow failure market dynamics in the coming years. Additionally, the US FDA has approved RETACRIT, a biosimilar of epoetin alfa. RETACRIT is now the first and only biosimilar erythropoiesis-stimulating agent (ESA) authorized for use in the United States.

Bone Marrow Failure Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025-2034. The landscape of bone marrow failure treatment has experienced a profound transformation with the uptake of novel medicines. These innovative therapies are redefining standards of care.

Bone Marrow Failure Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I/II stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for bone marrow failure emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders like MD, Professors, Directors, PhD, and others. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or bone marrow failure market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

DelveInsight's analysts connected with 15+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as the University of Florida, Great Ormond Street Hospital for Children NHS Foundation Trust etc. were contacted. Their opinion helps understand and validate bone marrow failure epidemiology and market trends.

Qualitative Analysis

We perform qualitative and market intelligence analysis using various approaches, such as SWOT and Conjoint analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The analyst analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry.

In efficacy, the trial's primary and secondary outcome measures are evaluated.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and a payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs) and third-party organizations that provide services and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a descriptive overview of bone marrow failure, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into bone marrow failure epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for bone marrow failure is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the bone marrow failure market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM bone marrow failure market.

Bone Marrow Failure Report Insights

Bone Marrow Failure Report Insights

• Patient Population
• Therapeutic Approaches
• Bone Marrow Failure Pipeline Analysis
• Bone Marrow Failure Market Size and Trends
• Market Opportunities
• Impact of Upcoming Therapies

Bone Marrow Failure Report Key Strengths

• Ten Years Forecast
• 7MM Coverage
• Bone Marrow Failure Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Bone Marrow Failure Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

• What was the bone marrow failure market share (%) distribution in 2024 and what it would look like in 2034?
• What would be the bone marrow failure total market size as well as market size by therapies across the 7MM during the study period (2020-2034)?
• What are the key findings about the market across the 7MM and which country will have the largest bone marrow failure market size during the study period (2020-2034)?
• At what CAGR, the bone marrow failure market is expected to grow at the 7MM level during the study period (2020-2034)?
• What would be the bone marrow failure market growth till 2034?
• What are the disease risks, burdens, and unmet needs of bone marrow failure?
• What is the historical bone marrow failure patient pool in the United States, EU4 (Germany, France, Italy, and Spain), and the UK, and Japan?
• What will be the growth opportunities across the 7MM concerning the patient population of bone marrow failure?
• Amon the 7MM which country would have the most prevalent cases of bone marrow failure?
• At what CAGR the population is expected to grow across the 7MM during the study period (2020-2034)?
• How many companies are developing therapies for the treatment of bone marrow failure?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of bone marrow failure?
• What are the key collaborations (industry-industry, industry-academia), Mergers and acquisitions, and licensing activities related to bone marrow failure therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the key designations that have been granted for the emerging therapies for bone marrow failure?
• What are the 7MM historical and forecasted market of bone marrow failure?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the bone marrow failure market.
• To understand the future market competition in the bone marrow failure market and insightful review of the SWOT analysis of bone marrow failure.
• Organize sales and marketing efforts by identifying the best opportunities for bone marrow failure in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the bone marrow failure market.
• To understand the future market competition in the bone marrow failure.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology of Bone Marrow Failure

6. Bone Marrow Failure Market Overview at a Glance

• 6.1. Market Share (%) Distribution of Bone Marrow Failure by Therapies in 2024
• 6.2. Market Share (%) Distribution of Bone Marrow Failure by Therapies in 2034

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Signs and Symptoms
• 7.3. Causes
• 7.4. Diagnosis
  • 7.4.1. Diagnosis Guidelines
  • 7.4.2. Diagnosis Algorithm

8. Treatment

• 8.1. Treatment Guidelines
• 8.2. Treatment Algorithm

9. Epidemiology and Patient Population of Bone Marrow Failure

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Total Incident Cases of Bone Marrow Failure in the 7MM
• 9.4. The United States
  • 9.4.1. Total Incidence Cases of Bone Marrow Failure in the United States
  • 9.4.2. Total Inherited Subtypes-specific Incident Cases of Bone Marrow Failure in the United States
  • 9.4.3. Age-specific Incident Cases of Bone Marrow Failure in the United States
  • 9.4.4. Etiology-specific Incident Cases of Bone Marrow Failure in the United States
• 9.5. EU4 and the UK
  • 9.5.1. Total Incidence Cases of Bone Marrow Failure in EU4 and the UK
  • 9.5.2. Total Inherited Subtypes-specific Incident Cases of Bone Marrow Failure in EU4 and the UK
  • 9.5.3. Age-specific Incident Cases of Bone Marrow Failure in EU4 and the UK
  • 9.5.4. Etiology-specific Incident Cases of Bone Marrow Failure in EU4 and the UK
• 9.6. Japan
  • 9.6.1. Total Incidence Cases of Bone Marrow Failure in Japan
  • 9.6.2. Total Inherited Subtypes-specific Incident Cases of Bone Marrow Failure in Japan
  • 9.6.3. Age-specific Incident Cases of Bone Marrow Failure in Japan
  • 9.6.4. Etiology-specific Incident Cases of Bone Marrow Failure in Japan

10. Patient Journey of Bone Marrow Failure

11. Marketed Therapies of Bone Marrow Failure

• 11.1. Key Competitors
• 11.2. REVOLADE/PROMACTA (eltrombopag): Novartis
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestone
  • 11.2.3. Other Development Activities
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Clinical Development
    • 11.2.5.1. Clinical Trials Information
  • 11.2.6. Analyst Views
• 11.3. PIASKY (crovalimab): Chugai Pharmaceutical/Roche
  • 11.3.1. Product Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Development Activities
  • 11.3.4. Clinical l Development
    • 11.3.4.1. Clinical Trials Information
  • 11.3.5. Safety and Efficacy
  • 11.3.6. Analyst Views

12. Emerging Therapy of Bone Marrow Failure

• 12.1. Key Competitors
• 12.2. EXG34217: Elixirgen Therapeutics
  • 12.2.1. Product Description
  • 12.2.2. Other Development Activities
  • 12.2.3. Clinical Development
    • 12.2.3.1. Clinical Trials Information
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Analyst Views

13. Bone Marrow Failure: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Market Outlook
• 13.3. Conjoint Analysis
• 13.4. Key Market Forecast Assumptions
  • 13.4.1. Cost Assumptions and Rebates
  • 13.4.2. Price Trends
  • 13.4.3. Analogue Assessment
  • 13.4.4. Launch Year and Therapy Uptakes
• 13.5. Total Market Size of Bone Marrow Failure in the 7MM
• 13.6. Market Size of Bone Marrow Failure by Therapies in the 7MM
• 13.7. The United States Market Size
  • 13.7.1. Total Market Size of Bone Marrow Failure in the United States
  • 13.7.2. Market Size of Bone Marrow Failure by Therapies in the United States
• 13.8. EU4 and the UK Market Size
  • 13.8.1. Total Market Size of Bone Marrow Failure in EU4 and the UK
  • 13.8.2. Market size of Bone Marrow Failure by Therapies in EU4 and the UK
• 13.9. Japan Market Size
  • 13.9.1. Total Market Size of Bone Marrow Failure in Japan
  • 13.9.2. Market Size of Bone Marrow Failure by Therapies in Japan

14. Unmet Needs of Bone Marrow Failure

15. SWOT Analysis of Bone Marrow Failure

16. KOL Views of Bone Marrow Failure

17. Market Access and Reimbursement

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight